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An outbreak of isoniazid-resistant tuberculosis first 
identified in London has now been ongoing for 20 
years, making it the largest drug-resistant outbreak of 
tuberculosis documented to date worldwide. We iden-
tified culture-confirmed cases with indistinguishable 
molecular strain types and extracted demographic, 
clinical, microbiological and social risk factor data 
from surveillance systems. We summarised changes 
over time and used kernel-density estimation and 
k-function analysis to assess geographic clustering. 
From 1995 to 2014, 508 cases were reported, with a 
declining trend in recent years. Overall, 70% were male 
(n = 360), 60% born in the United Kingdom (n = 306), 
39% white (n = 199), and 26% black Caribbean (n = 134). 
Median age increased from 25 years in the first 5 years 
to 42 in the last 5. Approximately two thirds of cases 
reported social risk factors: 45% drug use (n = 227), 
37% prison link (n = 189), 25% homelessness (n = 125) 
and 13% alcohol dependence (n = 64). Treatment was 
completed at 12 months by 52% of cases (n = 206), and 
was significantly lower for those with social risk fac-
tors (p < 0.05), but increased over time for all patients 
(p < 0.05). The outbreak remained focused in north 
London throughout. Control of this outbreak requires 
continued efforts to prevent and treat further active 
cases through targeted screening and enhanced case 
management.
Introduction
Incidence rates of tuberculosis have fallen in many 
European countries in recent years, but were increas-
ing until 2009 in England and Wales, and have since 
remained relatively high [1]. In 2014, 6,520 cases were 
reported in England (12/100,000 inhabitants) and 
115 in Wales (4/100,000). The highest incidence rate 
(30/100,000) was reported in London, where 39% of 
cases in England resided [2]. Multidrug-resistant (MDR) 
disease poses a particular threat to tuberculosis con-
trol as it cannot be managed using standard treatment 
regimens. Resistance to a single first-line drug is a pre-
cursor for development of MDR-tuberculosis, and iso-
niazid resistance is the most commonly identified form 
of resistance worldwide [3].
In England and Wales, 6–7% of cases with drug-sus-
ceptibility results are resistant to isoniazid [2], and 
in 2013, 7% of isoniazid-resistant tuberculosis cases 
in England had a strain type known to be associated 
with an ongoing outbreak [4]. This outbreak was first 
identified in 2000 at a hospital in north London where 
three young men were diagnosed with an identical 
strain type of the Euro-American lineage within a week. 
Retrospective strain typing of isolates available at the 
time identified a further 15 cases, with the first case 
dating back to 1995 [5]. Cases have since been ascer-
tained prospectively, and the outbreak now spans 20 
years [6].
2 www.eurosurveillance.org
Epidemiological characteristics of this ongoing out-
break were last described for cases up to 2006 [7]. 
These cases have previously been shown to include a 
high proportion of young males, particularly of white or 
black Caribbean ethnicity, who were born in the United 
Kingdom (UK) and lived in north London. Cases were 
also significantly more likely to present with social risk 
factors including imprisonment, unemployment, drug 
use or sex work [5,7,8]. An Outbreak Control Committee 
(OCC) established in 2000 recommended action on 
interagency working, improved identification and man-
agement of cases including use of directly observed 
therapy (DOT) and contact tracing, and improved con-
trol in prisons [9].
As cases continue to be reported 20 years since the 
first identified case, this cluster now represents one 
of the largest documented outbreaks worldwide of 
drug-resistant tuberculosis. In this study, we aimed 
to describe the evolution of the outbreak in time and 
space and discuss implications for future tuberculosis 
control.
Methods
Outbreak case definition and data sources
Cases were defined as individuals diagnosed from 1995 
to 2014 in England and Wales with a Mycobacterium 
tuberculosis isolate that was indistinguishable from 
the outbreak strain. Following identification of the 
outbreak in January 2000, cases were ascertained 
prospectively by strain typing of all isoniazid-resistant 
isolates from patients resident in, or with known epi-
demiological links to, London. Prior to 2000, cases 
were ascertained retrospectively through review of 
microbiological databases and strain typing of identi-
fied isolates [7]. From 2010 onwards, strain typing was 
conducted on all tuberculosis isolates in England and 
Wales, regardless of links to London.
The outbreak strain was initially characterised using 
restriction fragment length polymorphism (RFLP) anal-
ysis and before 2000, the isolates selected for typing 
were those of isoniazid monoresistant organisms cul-
tured at four laboratories serving the area where first 
cases were reported. After 2000 all such strains across 
London were RFLP-typed, and from 2006 onwards, due 
to a change in routine practice, 24-locus mycobacte-
rial interspersed repetitive sequence variable-number 
tandem repeat (MIRU-VNTR) typing was used to iden-
tify the corresponding strain [7]. Strain typing was 
conducted at the Health Protection Agency National 
Mycobacterium Reference Laboratory.
We extracted information on outbreak-related cases 
from multiple data sources. Demographic, clinical, 
microbiological and treatment outcome data were pro-
vided by a bespoke outbreak database, and from the 
electronic surveillance systems for London (the London 
Tuberculosis Register, LTBR) and the rest of England 
and Wales (the Enhanced Tuberculosis Surveillance 
System, ETS). Information on social risk factors (drug 
use, link to prisons, including patients who were in 
prison at time of diagnosis, homelessness, alcohol 
dependence and mental health concerns) was col-
lected initially in the bespoke outbreak database, and 
from 2009 in surveillance systems.
Figure 1
Number of cases in the isoniazid-resistant tuberculosis outbreak by year, England and Wales, 1995–2014 (n = 508)
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We also extracted information on outbreak cases from 
data collected by Find and Treat, a pan-London tuber-
culosis outreach service [10]. This service aims to iden-
tify cases of tuberculosis in hard-to-reach populations, 
typically those with social risk factors, and support 
them to complete treatment. We identified outbreak-
related cases who had been screened and managed by 
the service, and used data to supplement information 
on social risk factors.
Databases were combined on the basis of unique iden-
tifiers, patient names and dates of birth. Patients with 
multiple episodes of tuberculosis with the outbreak 
strain were identified, but only the first period was 
included in analyses.
Epidemiological analysis
We plotted annual numbers of outbreak cases as 
an epidemic curve. We described demographic, 
Figure 2
Percentage of cases in the isoniazid-resistant tuberculosis outbreak by year and social risk factor, England and Wales, 
1999–2014
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clinical and microbiological characteristics of all cases 
in counts and proportions, and used the chi-squared 
test for trend to identify changes over time. For social 
risk factors, we calculated overall proportions and 
identified changes over time by plotting proportions of 
cases reporting risk factors by year.
We identified treatment outcomes at 12 months for 
non-MDR cases who were notified between 2002 and 
2013. MDR cases were excluded from this analysis 
because their planned treatment regime exceeds 12 
months; cases notified before 2002 were excluded 
as they did not have a date of treatment outcome 
recorded, and outcomes had not yet been collected for 
cases after 2013. We tested for changes in proportions 
of cases completing treatment over time and used the 
chi-squared test to compare proportions of cases with 
and without social risk factors who completed treat-
ment. Final known outcomes were also defined, and 
included cases notified before 2002, MDR cases noti-
fied before 2013, and incorporated 12- or 24-month 
treatment follow-up where appropriate.
We used Find and Treat data to identify the proportion 
of cases notified in London who had been screened by 
the service (cases from 2005 onwards), and referred 
for case management (cases from 2007 onwards). We 
calculated the proportions of patients referred to Find 
and Treat who had social risk factors, and used chi-
squared tests to compare the rates of treatment com-
pletion in patients referred to Find and Treat with those 
who were not.
Spatial analysis
We determined case locations using geocoded residen-
tial postcodes where available. Prison or clinic post-
codes were used where relevant for patients diagnosed 
while in prison or with no fixed abode. We plotted 
numbers of cases nationally by region and calculated 
incidence rates by London borough using population 
data from the 2001 census. We visualised the spatio-
temporal progression of the outbreak within London 
through a series of smoothed-incidence maps. Each 
map displays the spatial intensity of case locations in 
a 5-year period during the outbreak, generated through 
kernel-density estimation [11].
We further explored the spatial point pattern of cases 
in London through k-function analysis. The k-func-
tion is a method for detecting spatial clustering and 
is defined as the expected number of cases within a 
given distance from an arbitrary case location [12]. 
First, we tested the hypothesis that the points were 
completely spatially random by comparing the k-func-
tion of the observed point locations with the func-
tion generated by 99 simulated point patterns. We 
then tested the hypothesis that the locations of cases 
in the first 10 years of the outbreak were part of the 
same spatial distribution as those in the second dec-
ade by calculating their cross k-function. This is the 
number of points from one distribution within a range 
of distances of a typical point from the other distribu-
tion [11]. The observed cross k-function was compared 
with the functions defined by 99 simulations based on 
random re-labelling of the joint spatial distribution of 
Figure 3
Eligibility criteria for cases included in analyses of treatment outcomes and Find and Treat data, isoniazid-resistant 
tuberculosis outbreak, England and Wales, 1995–2014
16 cases excluded: notified in 2014, 
treatment outcomes not yet available
508 cases: analysis of 
all cases in outbreak
491 cases: analysis of 
final known outcome
217 cases: analysis of 
cases available for screening 
by Find and Treat
137 cases: analysis of cases 
available to be referred 
to Find and Treat
212 cases excluded: notified before 2005 
(Find and Treat started screening in 2005). 
62 cases excluded: notified outside London 
(Find and Treat operates in London)
80 cases excluded: notified before 
2007 (Find and Treat started case 
management service in 2007)
1 case excluded: MDR, notified in 
2013, treatment regime > 12 months
15 cases excluded: MDR, treatment 
regime > 12 months 80 cases excluded: 
notified before 2002, outcome date 
not known
396 cases: analysis 
of 12-month outcome
MDR: multidrug-resistant.
Black boxes show analyses, blue boxes show exclusions.
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points to the two time periods. If the observed function 
lay within the upper and lower bounds of these limits, 
this would be consistent with the null hypothesis that 
the points were part of a common spatial distribution.
Data management, validation and analysis were per-
formed using R 3.1 and Stata 13.0. The R package 
spatstat was used for kernel-density and k-function 
analyses [13].
Results
From 1995 to 2014, 508 cases with the isoniazid-
resistant tuberculosis outbreak strain were identified. 
The epidemic curve (Figure 1) shows that, after initial 
ascertainment of the outbreak in 2000, the number of 
cases rose steeply, reaching a peak of 49 in 2006. After 
a subsequent decrease in numbers, there appears to 
have been a second peak in 2011, followed by another 
decline in cases.
Characteristics of cases
Table 1 presents the demographic characteristics of 
cases in this outbreak by 5-year period. The majority of 
cases (71%) were male; of white (39%), black Caribbean 
(26%) or black African (13%) ethnicity; and born in the 
UK (60%). There were no significant changes in propor-
tions of these characteristics over time (chi-squared 
trend p = 0.97, 0.39, and 0.28 for sex, ethnicity and 
place of birth respectively). The median age of cases 
increased from 25 years (range 6–71, interquartile 
range (IQR) 21–28) in 1995–1999 to 42 in 2010–2014 
(range 12–79, IQR 31–49); and there was a significant 
increase in the proportion of cases aged 45–64 years 
over the outbreak (chi-squared trend: p < 0.001).
Most cases (85%) had pulmonary tuberculosis, and 
this proportion did not change over time (chi-squared 
trend: p = 0.83). All cases had isoniazid-resistant dis-
ease; there were 14 cases of MDR-tuberculosis (3%), 
of which nine were MDR at their initial drug resistance 
test, and five were initially isoniazid-resistant but sub-
sequently acquired resistance to rifampicin. One MDR 
case additionally developed pyrazinamide resistance. 
Twenty-four patients were diagnosed with this strain 
on more than one occasion, half of whom had initially 
completed treatment. The longest interval between 
diagnoses was 14 years; median 3.5 years.
One or more social risk factors were reported for 308 
(61%) cases. History of drug use (227, 45%), links to 
prisons (189, 38%), and homelessness (125, 25%) 
were most frequently reported. Alcohol dependence 
(64, 13%) and mental health concerns (13, 3%) were 
reported less often. For 108 cases, two risk factors 
were reported (21%); for 66 cases, three risk factors 
(13%) and for 23 cases, four risk factors (5%). Figure 
2 displays the proportion of cases with each social 
risk factor by year. This demonstrates the continued 
importance of prisons and drug use over the duration 
of the outbreak; as well as the change in data-collec-
tion methods in 2009, which resulted in an increased 
proportion of cases reported with presence or absence 
of risk factors and decreased proportion with missing 
data. Prior to this, reports were commonly made only 
if a risk factor was present and left missing if absent.
Treatment outcomes and Find and Treat
Figure 3 defines the eligibility criteria for including 
cases in these analyses.
Treatment was completed by 206 (52%) of 396 eligi-
ble patients at 12 months, with a significant increase 
in this proportion during the outbreak (p < 0.05). Cases 
with at least one social risk factor had a significantly 
lower percentage of treatment completion at 12 months 
than those with none or missing information on social 
risk factors (42% and 67% respectively, chi-squared 
test: p < 0·05). Treatment completion was lowest for 
those with a history of homelessness (n = 42/125, 
39%), links to prisons (n = 58/189, 39%), or a history 
of drug use (n = 72/227, 52%). At final known outcome, 
372 (76%) of 491 eligible cases completed treatment, 
and those with at least one social risk factor also had a 
lower percentage of treatment completion (71% vs 82% 
for those with none or missing information on social 
risk factors, chi-squared test: p = 0·006). Twenty cases 
were reported to have died (4%). Tuberculosis is known 
to have contributed to the deaths of three patients at 
final known outcome, was incidental for seven, and 
Figure 4
Numbers of cases in the isoniazid-resistant outbreak in 
England (by Public Health England Region) and Wales, 
1995−2014 (n=505)
London
Midlands and East of England
North of England
South of England
Wales
416
44
28
15
2
0 50 100 km
N
Total number of cases is 505 because three cases had no 
geographical information. Contains Ordnance Survey data, Crown 
copyright and database right 2014.
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has an unknown link to the deaths of the remaining 10 
patients. Reasons for failing to complete treatment are 
shown in Table 2; 8.6% and 8.8% of cases had been 
lost to follow-up at 12 months and final known out-
come respectively.
The Find and Treat screening programme aims to iden-
tify cases of tuberculosis in ‘hard to reach’ populations 
and has been operating in London since 2005. During 
this period (2005–2013), it screened 11.5% (25/217) of 
the individuals which were subsequently found to be 
part of the outbreak. Since 2007, Find and Treat has 
also operated a case management service, and one 
quarter (35/137) of outbreak patients notified in London 
in this time period have been referred to the service. 
The majority of these patients had a history of home-
lessness (n = 30/35); drug use (n = 29/35) and links to 
prisons (n = 21/35). These patients were significantly 
less likely to have completed treatment at 12 months 
(15/35) compared with those who were not managed 
within the service (72/102, chi-squared p = 0.006). 
However, treatment completion at final known outcome 
Figure 5
Smoothed incidence maps of cases in the isoniazid-resistant tuberculosis outbreak in London, by 5-year time period, 
1995–2014
0 5 10 km
A. 1995−1999 B. 2000−2004
C. 2005−2009 D. 2010−2014
Case intensity
High Low
N
Spatial intensity determined using kernel-density estimation, bandwidth 597 m. Contains Ordnance Survey data, Crown copyright and 
database right 2014.
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was not significantly different between the two groups 
(26/35 vs 87/102; chi-squared test: p = 0.22).
Spatial analysis
All cases were successfully geocoded to locations in 
England and Wales, with the exception of which three 
had no location data. The majority of these cases (416, 
82%) lived in London; while the Midlands and East of 
England (44, 9%) reported the most cases of other 
regions (Figure 4). Within London, most cases were 
reported in north-east and north central areas, with the 
highest rates in the boroughs of Hackney and Haringey 
(45 and 34 cases per 100,000 population respectively), 
compared with 6 per 100,000 for the whole of London.
The smoothed incidence maps (Figure 5) show that the 
outbreak has remained largely concentrated in north 
London, with the highest spatial intensity of cases 
located in this region in all four time periods.
The k-function of the observed point locations (Figure 
6A) lies clearly outside the simulation envelope repre-
senting randomly generated point patterns. This dem-
onstrates that the data show spatial clustering above 
what would be expected by complete spatial random-
ness. The cross k-function (Figure 6B) compares the 
spatial distribution of the cases in the first and sec-
ond 10 years of the outbreak. The k-function of the 
observed data lies within the simulation envelope gen-
erated through random labelling of cases to different 
time periods. There was therefore no evidence that the 
spatial distribution of cases in London changed signifi-
cantly during the outbreak.
Discussion
This isoniazid-resistant tuberculosis outbreak has now 
been ongoing for 20 years, despite a recent decline 
in incidence. It has had a consistent focus in north 
London, particularly among socially marginalised pop-
ulations. Links to prisons, drug use, and a history of 
homelessness are important risk factors, and failure 
of these groups to complete treatment is likely to have 
perpetuated the outbreak.
Major impacts of this outbreak have included tuber-
culosis disease in over 500 individuals, at least three 
linked deaths, and reinfection or relapse in 24 cases. 
Multidrug-resistance has emerged in this strain, and 
appears to have been transmitted between cases, 
as nine patients presented with an initial drug resist-
ance test that was MDR. There are also potentially 
thousands of further individuals who have undetected 
infections, given that the lifetime risk of developing 
active disease following infection is estimated at 10% 
[14]. Furthermore, this outbreak has contributed con-
siderable economic costs to health and social care 
services: Management of an uncomplicated case of 
tuberculosis is estimated to cost GBP  5,000 (approxi-
mately EUR 5,790), while drug-resistant cases can cost 
more than 10 times this amount, before taking into 
Figure 6
K-function analysis of spatial clustering in isoniazid-resistant tuberculosis outbreak in London, 1995–2014; A: K-function 
test of complete spatial randomness; B: Cross k-function comparing first and second 10 years of outbreak
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account use of additional resources associated with 
outbreak investigations such as contact tracing and 
outbreak control team meetings [15].
The outbreak has proved particularly challenging to 
control despite great efforts overseen by the dedicated 
OCC established in 2000. It has consistently been 
associated with ‘hard to reach’ populations includ-
ing those with a history of drug use, homelessness or 
imprisonment. Recommendations implemented by the 
OCC which attempted to target these groups included 
extension of contact tracing beyond household con-
tacts to close social contacts, promulgation of advice 
relating to specific drug regimens for treatment, and 
expanded use of DOT [9]. The OCC met regularly and 
reviewed progress and implementation, with improve-
ments seen in numbers of contacts traced per case and 
treatment completion, but the decline in cases was 
slow to occur. In more recent years, the Find and Treat 
mobile screening unit has contributed to control of the 
outbreak. Approximately one in 10 outbreak cases was 
screened by this service since it started operating, and 
it was also an effective service for managing complex 
patients: In this outbreak, patients managed by Find 
and Treat had a higher prevalence of social risk factors, 
but there was no significant difference in final treat-
ment completion rates in these patients compared with 
others in the outbreak.
Table 1
Demographic characteristics of cases in the isoniazid-resistant tuberculosis outbreak, England and Wales, 1995–2014
1995–1999 
n (%)
2000–2004 
n (%)
2005–2009 
n (%)
2010–2014 
n (%)
All 
n (% of total)
All cases 21 191 176 120 508
Sex 
Male 13 (61.9) 139 (72.8) 122 (69.3) 86 (71.7) 360 (70.9)
Female 8 (38.1) 52 (27.2) 54 (30.7) 34 (28.3) 148 (29.1)
Age (years) 
Median 25 35 36 42 36
< 15 1 (4.8) 1 (0.5) 5 (2.8) 2 (1.7) 9 (1.8)
15–24 9 (42.9) 31 (16.2) 22 (12.5) 8 (6.7) 70 (13.8)
25–34 8 (38.1) 60 (31.4) 53 (30.1) 29 (24.2) 150 (29.5)
35–44 1 (4.8) 58 (30.4) 55 (31.3) 31 (25.8) 145 (28.5)
45–64 1 (4.8) 34 (17.8) 35 (19.9) 46 (38.3) 116 (22.8)
> 65 1 (4.8) 7 (3.7) 6 (3.4) 4 (3.3) 18 (3.5)
Ethnic group 
White 8 (38.1) 59 (30.9) 73 (41.5) 59 (49.2) 199 (39.2)
Black Caribbean 4 (19.0) 59 (30.9) 49 (27.8) 22 (18.3) 134 (26.4)
Black African 3 (14.3) 34 (17.8) 20 (11.4) 10 (8.3) 67 (13.2)
Indian 2 (9.5) 7 (3.7) 6 (3.4) 7 (5.8) 22 (4.3)
Black other 1 (4.8) 4 (2.1) 8 (4.5) 5 (4.2) 18 (3.5)
Other 1 (4.8) 18 (9.4) 14 (8.0) 15 (12.5) 43 (8.4)
Unknown 2 (9.5) 10 (5.2) 6 (3.4) 2 (1.7) 20 (3.9)
UK-born 
Yes 15 (71.4) 95 (49.7) 114 (64.8) 82 (68.3) 306 (60.2)
No 4 (19.0) 82 (42.9) 51 (29.0) 35 (29.2) 172 (33.9)
Unknown 2 (9.5) 14 (7.3) 11 (6.3) 3 (2.5) 30 (5.9)
Country/area of 
birth if not UK-born 
Sub-Saharan Africaa 1 (4.8) 24 (12.6) 20 (11.4) 8 (6.7) 53 (10.4)
Jamaica 0 (0) 17 (8.9) 10 (5.7) 5 (4.2) 32 (6.3)
Ireland 1 (4.8) 14 (7.3) 2 (1.1) 6 (5.0) 23 (4.5)
Indian 
Subcontinentb 1 (4.8) 4 (2.1) 3 (1.7) 6 (5.0) 14 (2.8)
Other 0 (0) 20 (10.5) 15 (8.5) 10 (8.3) 45 (8.9)
Unknown 3 (14.3) 17 (8.9) 12 (6.8) 3 (2.5) 35 (6.9)
UK: United Kingdom.
a Includes cases born in Angola, Congo, Eritrea, Ethiopia, Gambia, Ghana, Kenya, Liberia, Mauritania, Nigeria, Sierra Leone, Somalia, 
Tanzania, Uganda, Zambia and Zimbabwe.
b Includes cases born in India, Bangladesh, Pakistan and Sri Lanka.
9www.eurosurveillance.org
Our analysis provides some insights into the natural 
history of this outbreak and how it has progressed. In 
spite of its long duration, the outbreak has remained 
fairly circumscribed in north London, and characteris-
tics of populations affected have remained relatively 
stable, although the age of the patients at notifica-
tion did increase over time. The smoothed incidence 
maps and k-function analyses demonstrate distinct 
spatial clustering which persisted in the same region 
of north London throughout. These observations are 
consistent with intensive transmission among a social 
cohort approximately 20 years ago, whose infections 
have gradually progressed to active disease. If a great 
deal of ongoing transmission had been occurring out-
with these groups, it would be expected that cases 
would have become more widely disseminated with 
smaller clusters arising in dispersed geographic areas. 
Detailed genetic analyses of a selection of outbreak 
isolates found little or no associated fitness cost and 
the presence of specific deletions that could be a pecu-
liar feature of the strains and help explain their persis-
tence over the very many years [16].The epidemic curve 
had a two-wave pattern, with an initial peak which may 
represent cases whose infections rapidly progressed to 
disease, and a later peak potentially driven by those 
presenting with symptoms following a longer period of 
latency. Alternatively, the second wave of cases may 
have resulted from a second period of intensive trans-
mission. Whole genome sequencing of isolates could 
be used to investigate these hypotheses by construct-
ing a phylogenetic tree that identifies likely chains of 
transmission [17].
This analysis represents the largest documented out-
break of drug-resistant tuberculosis to date. Previous 
outbreaks of comparable size have been reported in 
New York City [18-20] and South Africa [21,22]. Both 
incidents were linked to nosocomial transmission 
among HIV-positive patients, which have not been 
important factors in this outbreak [7]. There are more 
commonalities between this outbreak and one that 
occurred in Stockholm, Sweden between 1996 and 
2005, comprising 96 cases [23,24]. The Stockholm out-
break was also characterised by confinement of cases 
to a distinct demographic group in a small geographic 
area, resistance to isoniazid, and had an epidemic 
curve with a two-wave pattern. This indicates the 
importance of community transmission of tuberculosis 
within European cities, and the need to focus control 
measures on affected groups.
Our results therefore have implications for future con-
trol of this outbreak and for control of tuberculosis 
more widely. We recommend targeted screening of 
high-risk individuals (for example in prisons) to prevent 
further active cases, and enhanced case management 
to support patients to complete treatment. Continued 
support of the Find and Treat tuberculosis outreach 
service, which provides a cost-effective approach to 
case finding [10] and has successfully identified and 
managed complex patients in this outbreak, should 
help to achieve this. We additionally recommend fol-
lowing National Institute for Health and Care Excellence 
guidance for tackling tuberculosis among hard-to-reach 
groups [15]. This includes standardised risk assess-
ment for all tuberculosis patients; better recording and 
monitoring of contact tracing, and expanded use of 
DOT, which is used infrequently in London compared 
with other parts of the world [25]. In the wider context 
of tuberculosis outbreak control, we recommend regu-
lar reviews of the epidemiology and spatial distribution 
of tuberculosis clusters linked by molecular strain typ-
ing. This will enable better understanding of the impor-
tant factors associated with transmission, tracking the 
extent of spatial dispersion of outbreak strains, and 
improved targeting of control measures.
A strength of this study is that we combined data 
from multiple sources including two surveillance sys-
tems, a bespoke outbreak database, and data from 
the tuberculosis outreach service, Find and Treat. This 
enabled us to describe all reported cases that have 
Table 2
Treatment outcomes of cases in the isoniazid-resistant tuberculosis outbreak, England and Wales, 2002–2013 (12-month 
outcome) and 1995–2013 (final known outcome)
Outcome 
12-month outcome  
(cases 2002–2013)a 
n (%)
Final known outcome  
(cases 1995–2013)b 
n (%)
Completed 206 (52.0) 372 (75.8)
Still on treatment 66 (16.7) 11 (2.2)
Lost to follow-up 34 (8.6) 43 (8.8)
Died 12 (3.0) 20 (4.1)
Transferred out 10 (2.5) 17 (3.5)
Unknown / Not complete – unknown reason 68 (17.2) 28 (5.7)
Total 396 491 
a Excluding all multidrug-resistant cases.
b Excluding multidrug-resistant case notified in 2013.
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been associated with the outbreak, and ensured best 
possible completeness of variables. However, there 
were also limitations with these data: We are unlikely 
to have ascertained all cases affected in the outbreak 
because we used only culture-confirmed cases, exclud-
ing those without appropriate strain-typing information 
regardless of epidemiological links. This also means 
that we are likely to have overestimated the prevalence 
of pulmonary disease in this outbreak. The number of 
cases that occurred before 2000 is likely to have been 
underestimated as cases were ascertained retrospec-
tively, and before 2010 cases notified outside London 
were not typed unless there were known epidemiologi-
cal links to the outbreak. Owing to the change in rou-
tine microbiological testing procedures from RFLP to 
MIRU-VNTR typing, the case definition for this outbreak 
also changed. It is therefore possible that these cases 
are not part of the same outbreak. However, all cases 
were isoniazid-resistant and epidemiological charac-
teristics of cases did not change significantly following 
the change in strain-typing methodology. This sug-
gests that the updated case definition was appropri-
ate, but this is being confirmed through whole genome 
sequencing of isolates defined through the two differ-
ent methods.
Another limitation of this analysis is that we were 
unable to assess the importance of risk factors which 
are not included in routine surveillance. These include 
commercial sex work and unemployment, which have 
previously been found to be linked to this outbreak, 
and HIV status, which is not thought to be an impor-
tant factor [7]. Estimates for prevalence of social risk 
factors also represent minimum likely values, owing 
to non-ascertainment, non-disclosure and inconsist-
ent definitions, particularly before 2009 when these 
fields were introduced to routine surveillance systems. 
We therefore did not assess the relative importance of 
risk factors in this outbreak through a formal case con-
trol study. However, surveillance data shows that the 
proportion of all London tuberculosis cases reported 
between 2009 and 2014 who had one or more social 
risk factor was substantially lower than for cases in 
this outbreak reported over the same period (ca 10% 
and 40% respectively) [6]. The shift towards older age 
groups observed here has also not been observed in 
London cases more widely, and, contrary to the pattern 
in this outbreak, highest overall rates within London 
have been in north-west areas [6]. It is therefore likely 
that the characteristics identified here are specific to 
this outbreak and do not merely reflect the epidemiol-
ogy of tuberculosis patients as a whole.
Finally, there were limitations to the statistical and 
spatial methods used in this analysis. We used the chi-
squared test for trend to identify changes in patient 
characteristics over time. An assumption of this test is 
that the proportions did not, for example, increase and 
then decrease as the outbreak progressed. We checked 
for this possibility by plotting these characteristics as 
a function of time. Spatial analyses were based on 
point locations of cases stratified by 5- and 10-year 
time periods. This provides an incomplete picture of 
the true spatial distribution of the outbreak and could 
have masked intra-period changes in distributions. 
However, the smoothed incidence maps demonstrate a 
clear and persistent focal point the north of the city, so 
it is unlikely that these factors have had a substantial 
impact on the conclusions.
Tuberculosis in Europe is increasingly a problem that 
is concentrated in large cities [26]. This study demon-
strates that outbreaks in cities, even in low incidence 
countries, can persist for many years through com-
munity transmission. Resolving this outbreak of drug-
resistant disease, and prevention of future outbreaks, 
will therefore be a key factor in strengthening tuber-
culosis control in Europe. As recognised by the recent 
Collaborative Tuberculosis Strategy for England, this 
will require that best practice in clinical care, social 
support and public health are brought together [27].
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